Avricore Health (AVCRF) Cash & Equivalents (2009 - 2025)

Avricore Health has disclosed Cash & Equivalents across 17 years of filings, most recently posting $163436.9 for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 79.84% year-over-year to $163436.9; the TTM figure through Dec 2025 stood at $163436.9 (down 79.84% YoY), while the FY2025 annual figure was $163125.8, down 80.28% from the prior year.
• Cash & Equivalents fell to $163436.9 in Q4 2025, from $386389.6 in the prior quarter.
• Over the last five years, Cash & Equivalents for AVCRF reached as high as $2.0 million in Q1 2021 and fell as low as $163436.9 in Q4 2025.
• The 5-year median for Cash & Equivalents is $594680.2 (2024), against an average of $823615.9.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 6079.41% — and 2025, when it sank 79.84%.
• A 5-year view of Cash & Equivalents shows it stood at $1.6 million in 2021, then sank by 71.37% to $457144.1 in 2022, then plunged by 55.56% to $203151.2 in 2023, then surged by 299.02% to $810621.8 in 2024, then slumped by 79.84% to $163436.9 in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $163436.9, $386389.6, and $617201.3 for Q4 2025, Q3 2025, and Q2 2025 respectively.